---
title: "Piramal Pharma Ltd (PPLPHARMA) — Share Price, Financials & Analysis"
symbol: "PPLPHARMA"
company: "Piramal Pharma Ltd"
canonical: "https://tapetide.com/stocks/PPLPHARMA"
isin: "INE0DK501011"
nse_symbol: "PPLPHARMA"
bse_code: "543635"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 28148.69
generated_at: "2026-09-13T19:25:33.140Z"
---

# Piramal Pharma Ltd (PPLPHARMA)

Canonical page: https://tapetide.com/stocks/PPLPHARMA

## Company

- **NSE Symbol:** PPLPHARMA
- **BSE Code:** 543635
- **ISIN:** INE0DK501011
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2022-10-19
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** piramal.com

## About

Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments
(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).
Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions[1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion[2] and Diagnostic Services was sold to Super Religare Laboratories (SRL)[3]

## Latest Price

- **Price:** ₹211.35
- **Change:** -1.14 (-0.54%)
- **Open:** ₹210.59
- **Day High:** ₹214.45
- **Day Low:** ₹208.68
- **Previous Close:** ₹212.49
- **Volume:** 3408833
- **As Of:** 2026-09-11T10:24:53+00:00

## Key Fundamentals

Observed at 2026-09-11T04:34:45.017535Z.

- **Market Cap:** ₹28148.69 Cr
- **Classification:** Smallcap
- **P/E (reported):** -90
- **EPS (TTM):** ₹-2.36
- **EPS (reported):** ₹0.3
- **Book Value:** ₹61.34
- **Price to Book:** 3.46
- **Dividend Yield:** 0.07%
- **ROE:** -3.99%
- **ROCE:** 1.25%
- **Debt to Equity:** 0.7
- **Revenue (yearly):** ₹9082.4 Cr
- **Net Income:** ₹-325.9 Cr
- **EBITDA:** ₹1134.9 Cr
- **52-Week High:** ₹231.93
- **52-Week Low:** ₹132.3
- **RSI (14):** 52.27

## Tapetide Score

- **Score:** 30 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Rising
- **Percentile:** 2 (of 4473 scored stocks)
- **Confidence:** 93%
- **Data coverage:** 86%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 14.8 | 9% |
| growth | 7.12 | 9% |
| momentum | 69.93 | 12% |
| ownership | 7.24 | 24% |
| quality | 19.74 | 22% |
| valuation | 59.46 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 3.44 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.03% over past five years.
- Company has a low return on equity of -0.88% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 85.21% | 64.51% | 115.63% |
| ebitda margin growth | -11.67% | -26.51% | -23.92% | -30.28% |
| net income growth | -688.64% | -457.74% | -31% | -186.68% |
| revenue growth | -15.38% | -2.19% | 8% | 7% |
| roce | -36.01% | -82.19% | -78.22% | 4.62% |
| roe | 685.84% | -456.25% | -0.88% | -171.12% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1911 | 1959 | 2552 | 1951 | 2242 | 2204 | 2754 | 1934 | 2044 | 2140 | 2752 | 2270 |
| Expenses | 1646 | 1690 | 2022 | 1747 | 1900 | 1866 | 2193 | 1827 | 1885 | 1944 | 2291 | 2075 |
| Operating Profit | 266 | 268 | 530 | 204 | 342 | 338 | 561 | 107 | 159 | 196 | 461 | 195 |
| OPM % | 14 | 14 | 21 | 10 | 15 | 15 | 20 | 6 | 8 | 9 | 17 | 9 |
| Other Income | 68 | 43 | 8 | 42 | 78 | 29 | 58 | 98 | 80 | 12 | -116 | 109 |
| Interest | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 | 82 | 89 | 83 | 88 |
| Depreciation | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 | 203 | 213 | 218 | 224 |
| Profit before tax | 40 | 19 | 227 | -45 | 120 | 67 | 273 | -79 | -46 | -94 | 43 | -7 |
| Tax % | 87 | 48 | 55 | 97 | 81 | 94 | 44 | 3 | 115 | 45 | 121 | 830 |
| Net Profit | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 | -99 | -136 | -9 | -69 |
| EPS in Rs | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | -0.52 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 6315 | 6559 | 7082 | 8171 | 9151 | 8869 | 9205 |
| Expenses | 4887 | 5609 | 6453 | 6974 | 7706 | 7947 | 8195 |
| Operating Profit | 1428 | 950 | 629 | 1197 | 1445 | 922 | 1010 |
| OPM % | 23 | 14 | 9 | 15 | 16 | 10 | 11 |
| Other Income | 230 | 319 | 272 | 172 | 208 | 74 | 86 |
| Interest | 163 | 198 | 344 | 448 | 422 | 341 | 343 |
| Depreciation | 545 | 586 | 677 | 741 | 816 | 831 | 858 |
| Profit before tax | 949 | 485 | -120 | 179 | 415 | -176 | -104 |
| Tax % | 12 | 22 | 55 | 90 | 78 | 85 | — |
| Net Profit | 835 | 376 | -186 | 18 | 91 | -326 | -314 |
| EPS in Rs | — | — | -1.41 | 0.13 | 0.69 | -2.45 | -2.36 |
| Dividend Payout % | 0 | 18 | 0 | 82 | 20 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 995 | 1186 | 1193 | 1323 | 1324 | 1327 |
| Reserves | 4610 | 5511 | 5580 | 6588 | 6801 | 6835 |
| Borrowings | 3025 | 4128 | 5637 | 4710 | 4856 | 5675 |
| Other Liabilities | 2047 | 1781 | 1893 | 2461 | 2447 | 3770 |
| Total Liabilities | 10677 | 12605 | 14303 | 15083 | 15429 | 17607 |
| Fixed Assets | 6105 | 6879 | 7469 | 7990 | 8133 | 8684 |
| CWIP | 627 | 1172 | 1419 | 1116 | 977 | 1100 |
| Investments | 123 | 267 | 639 | 385 | 291 | 437 |
| Other Assets | 3822 | 4286 | 4777 | 5592 | 6028 | 7386 |
| Total Assets | 10677 | 12605 | 14303 | 15083 | 15429 | 17607 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 598 | 766 | 484 | 1005 | 892 | 1653 |
| Cash from Investing Activity | -4464 | -1737 | -1334 | -416 | -488 | -820 |
| Cash from Financing Activity | 3977 | 794 | 818 | -422 | -441 | -39 |
| Net Cash Flow | 110 | -177 | -32 | 166 | -37 | 794 |
| Free Cash Flow | -5 | -91 | -461 | 294 | 233 | 776 |
| CFO/OP | 52 | 98 | 107 | 97 | 85 | 202 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 91 | 99 | 93 | 95 | 94 | 89 |
| Inventory Days | 218 | 207 | 227 | 269 | 261 | 345 |
| Days Payable | 163 | 153 | 161 | 190 | 173 | 279 |
| Cash Conversion Cycle | 147 | 153 | 159 | 174 | 182 | 155 |
| Working Capital Days | 44 | 36 | 13 | 21 | 60 | 44 |
| ROCE % | — | 7 | 2 | 5 | 6 | 3 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 35.02% | 35.02% | 35.02% | 34.95% | 34.95% | 34.95% | 34.95% | 34.86% | 34.86% | 34.86% | 34.86% | 34.8% |
| FIIs | 32.37% | 32.51% | 30.59% | 31.42% | 31.73% | 31.68% | 31.49% | 30.86% | 30.27% | 29.66% | 30.18% | 12.52% |
| DIIs | 8.02% | 9.68% | 12.12% | 12.95% | 13.81% | 14.1% | 14.78% | 14.26% | 14.89% | 15.69% | 15.61% | 14.57% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 16.95% | 15.57% | 15.13% | 13.94% | 13.29% | 13.29% | 13.11% | 14.07% | 14.12% | 14.11% | 13.74% | 14.54% |
| Others | 7.64% | 7.22% | 7.14% | 6.74% | 6.22% | 5.98% | 5.66% | 5.95% | 5.86% | 5.69% | 5.61% | 23.57% |
| No. of Shareholders | 297225 | 292312 | 297996 | 306398 | 359751 | 418442 | 432843 | 458430 | 462511 | 453830 | 450661 | 461096 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 4 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 215.82 | Sell |
| EMA (10) | 215.29 | Sell |
| SMA (20) | 213.86 | Sell |
| EMA (20) | 212.9 | Sell |
| SMA (50) | 199.58 | Buy |
| EMA (50) | 201.75 | Buy |
| SMA (100) | 184.29 | Buy |
| EMA (100) | 189.76 | Buy |
| SMA (200) | 172.65 | Buy |
| EMA (200) | 183.93 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 51.08 | Neutral |
| MACD (12,26,9) | 4.28 | Sell |
| Stochastic (14,3,3) | 29.56 | Neutral |
| ADX (14) | 30.77 | Buy |
| Williams %R (14) | -80.61 | Buy |
| ATR (14) | 7.51 | High Volatility |
| ROC (12) | 0.03 | Buy |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 44.04 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 10 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 10 analyst ratings, observed at 2026-09-11T04:34:47.741378+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=062f3fdf-dfc4-4681-9897-b8d2c10da9d1.pdf) |
| 2026-09-03 | [Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cf25bde-73c9-49b6-aa24-bbbfaad9e61b.pdf) |
| 2026-08-26 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=D47DDDB2_2823_42AE_A281_735DC4D98C15_172138.pdf) |
| 2026-08-24 | [Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1fdac502-b9f8-4dc5-8ea1-e1f40aff255f.pdf) |
| 2026-08-18 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9DE6D096_ADD5_4B2D_85EF_C44E12ED123E_112951.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Acquisition](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b7efdf15-e246-42e5-8651-d72f3b479d79.pdf) |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9d00f78-6b15-4263-b15c-b37af6684304.pdf) |
| 2026-08-10 | [Announcement Under Regulation 30 (LODR)- Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4a0a2aaf-a71f-46c5-a4ee-5b238616b61d.pdf) |
| 2026-08-03 | [Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -Resumption Of Operations At CompanyS Facilities Located At Ahmedabad Gujarat](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d373b05d-53f8-4e47-a194-3d888c5c30a7.pdf) |
| 2026-07-30 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eac921f4-47cc-4fb9-aa48-c12aebcd6c89.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e945788-94c4-4aff-8aea-0dd4f7ef5047.pdf) |
| 2026-01-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1052a148-c60c-4716-ae9c-4a49d73d516a.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=613b1fb0-5d63-4527-8fb7-e67860d13044.pdf) |
| 2025-01-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0198dac-d4ee-42f4-bef0-7ce2fa830d79.pdf) |
| 2024-10-26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b45bd32-998e-4451-bf41-a95b0028c16a.pdf) |
| 2024-07-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6c1a28b-7865-404f-b326-1cd57ff20984.pdf) |
| 2024-05-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b81638c1-2532-47c6-804e-2cfffcb28dc8.pdf) |
| 2024-02-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7eae6a10-35a1-46aa-a7ef-05be49089434.pdf) |
| 2023-10-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bbea31c-3c22-4448-b5fe-2f81c4ab1e5c.pdf) |
| 2023-08-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49ee2aae-4c46-4f28-bc85-6d1a36850150.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e93324e9-e816-4887-b9ea-1d5fef4fce75.pdf) |
| 2026-04-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f612bec-8889-4faf-8782-45b686eba530.pdf) |
| 2026-01-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14e571e6-b421-4ea7-b782-bc5d3aaa33b7.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c3932c1-b587-4e35-9cd2-58ea4e3b0f0e.pdf) |
| 2025-07-29 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85945f2b-9feb-4628-bfd6-5969edbc57d9.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b428052b-efdb-4cb2-88e1-30e908216418.pdf) |
| 2024-05-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41fd3fe8-e3f8-4456-af9e-19ea97fc6dc9.pdf) |
| 2024-01-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=988929ae-4f86-4464-9f02-531ce8dfc696.pdf) |
| 2023-10-30 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0df15461-4929-4b6c-9f31-b2425ec7e285.pdf) |
| 2023-08-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be81733e-d7c1-4ca4-97c3-d580499dca23.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-29 | [Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dfa758e-bf28-4ac8-bffd-12c6705d51f8.pdf) |
| 2026-04-28 | [Results - Financial Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bfa77d87-a52e-4e97-8e0f-c39483803b14.pdf) |
| 2026-01-29 | [Results - Financial Results For The Quarter Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2871069a-9572-48d6-8443-199dd3b96fe8.pdf) |
| 2025-11-05 | [Results - Financial Results For Quarter Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32a65634-dd99-4062-b6d8-2c2f6dd69041.pdf) |
| 2025-07-28 | [Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f13fadb0-a355-4091-803d-ca4c581b32f6.pdf) |
| 2025-05-14 | [Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd0d01f2-e1cb-472b-9d81-b420114031a0.pdf) |
| 2025-01-28 | [Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=76dfe36d-67ad-467c-a249-f49765c60fd7.pdf) |
| 2024-10-23 | [Unaudited Financial Results For Quarter And Half Year Ended 30Th September 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd57c8cf-1d4a-4ed3-8967-4182ba3cbaac.pdf) |
| 2024-07-26 | [Financial Results For The Quarter Ended 30Th June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f697efe5-4196-4896-8241-84e6f3936ce6.pdf) |
| 2024-05-10 | [Audited Financial Results (Standalone & Consolidated) Of The Company For The Quarter And Year Ended 31St March, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3564c28a-e817-49ca-b6ce-4f3868f0fc76.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5efe2042-c068-4606-bd7b-731263eaa4e2.pdf) |
| 2026-04-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6af1c917-7f6f-4fd7-afa8-d2d922d0d7bd.pdf) |
| 2026-01-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94be2676-fca1-4eeb-9e5c-fa84c33674c3.pdf) |
| 2025-11-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f67db704-3ad8-48fe-baeb-efaaa2dc2d88.pdf) |
| 2025-07-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03caf78a-1ca0-4ca9-9e2c-4f8eec46ead1.pdf) |
| 2025-05-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ba18641e-a77f-4d2d-ad62-b50bc644d450.pdf) |
| 2025-01-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee092d7d-2fb3-45e0-8cfd-1cc325533a34.pdf) |
| 2024-10-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b745cfe-e39e-485e-9aad-b2d8615981f3.pdf) |
| 2024-09-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3419ae7-735b-499c-8840-4308d9b6a8a3.pdf) |
| 2024-07-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=773bd656-ff69-4552-9022-1a324a36e796.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c3419ae7-735b-499c-8840-4308d9b6a8a3.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=573fb590-bce6-42d4-9081-615a42319219.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/573fb590-bce6-42d4-9081-615a42319219.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eff008fb-5727-4869-a935-3b25ff3d280e.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b2a967d4-a3e8-4799-9372-08075b413bfc.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/15f5da78-aed7-4b3a-a11f-f18f57b84b80.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af25dd79-431c-43a1-99f3-9a6581e97515.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/af25dd79-431c-43a1-99f3-9a6581e97515.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/03caf78a-1ca0-4ca9-9e2c-4f8eec46ead1.pdf) |
| Jan 2024 | [Concall - Jan 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09998dde-6fa7-4362-a05f-36cb577314b1.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 6h - Board approved FY26 audited results, reappointed directors, appointed company secretary, and changed registered office effective 30 April 2026. | [Board Meeting Outcome for Outcome Of The Board Meeting Dated April 28, 2026 6h - Board approved FY26 audited results, reappointed directors, appointed company secretary, and changed registered office effective 30 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/104cce64-4562-43d0-b311-5532c209576f.pdf) |
| 6 Apr - NSE Sustainability assigned Piramal Pharma ESG rating 64 for FY2024-25, up from 61. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - ESG Rating 6 Apr - NSE Sustainability assigned Piramal Pharma ESG rating 64 for FY2024-25, up from 61.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4b841cd9-e3d1-4590-8785-52bf384d12a2.pdf) |
| 5h - Board approved FY26 audited results: PAT ₹700.01 crore, reappointed directors, appointed company secretary, changed registered office. | [Appointment of Company Secretary and Compliance Officer 5h - Board approved FY26 audited results: PAT ₹700.01 crore, reappointed directors, appointed company secretary, changed registered office.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f58ef014-fee8-4720-b8c5-cbb0b4a50720.pdf) |
| 5h - Board approved FY26 audited results, reappointed Nandini Piramal, Peter DeYoung, and named new company secretary. | [Announcement under Regulation 30 (LODR)-Change in Management 5h - Board approved FY26 audited results, reappointed Nandini Piramal, Peter DeYoung, and named new company secretary.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/67c2d96d-98b3-47b9-81a1-21570cea9ad0.pdf) |
| 5h - Board approved FY26 audited results, reappointed directors, appointed company secretary, and shifted registered office effective 30 Apr 2026. | [Announcement under Regulation 30 (LODR)-Change in Registered Office Address 5h - Board approved FY26 audited results, reappointed directors, appointed company secretary, and shifted registered office effective 30 Apr 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/21f4e662-25c2-49ed-aa10-ef8af3f217e4.pdf) |
| 4 May - Of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 May - Of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4b964a4c-eb4a-4931-997d-56d5c2fcbccc.pdf) |
| 4 May - Of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 May - Of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (LODR) Regulations, 2015](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4b964a4c-eb4a-4931-997d-56d5c2fcbccc.pdf) |
| 30 Apr - Transcript of 29 April 2026 conference call on audited Q4 and FY2026 results available on website. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Apr - Transcript of 29 April 2026 conference call on audited Q4 and FY2026 results available on website.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b2123b5-3ed6-4425-8d4e-c943a8382bc6.pdf) |
| 30 Apr - Transcript of 29 April 2026 conference call on audited Q4 and FY2026 results available on website. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Apr - Transcript of 29 April 2026 conference call on audited Q4 and FY2026 results available on website.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/9b2123b5-3ed6-4425-8d4e-c943a8382bc6.pdf) |
| 29 Apr - Piramal Pharma shared CFO and Company Secretary contact details for Regulation 30(5) compliance. | [Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations') 29 Apr - Piramal Pharma shared CFO and Company Secretary contact details for Regulation 30(5) compliance.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7e0c26d8-d0e4-4444-a52c-f4821161362f.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8a3aabd8-6aef-45b8-aa20-370bc162321a.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33c9f38c-0692-4e04-b789-77605f82aa29.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c09d72ec-f184-4eba-bcc8-93b26b846609.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/73a532ba-6b75-4bf8-a1b1-469e19ecf065.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:25:33.140Z.